Asset Details
Do you wish to reserve the book?
Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate
Do you wish to request the book?
Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate
2021
Overview
The mortality rates of COVID-19 vary widely across countries, but the underlying mechanisms remain unelucidated. We aimed at the elucidation of relationship between gut microbiota and the mortality rates of COVID-19 across countries. Raw sequencing data of 16S rRNA V3-V5 regions of gut microbiota in 953 healthy subjects in ten countries were obtained from the public database. We made a generalized linear model (GLM) to predict the COVID-19 mortality rates using gut microbiota. GLM revealed that low genus Collinsella predicted high COVID-19 mortality rates with a markedly low p -value. Unsupervised clustering of gut microbiota in 953 subjects yielded five enterotypes. The mortality rates were increased from enterotypes 1 to 5, whereas the abundances of Collinsella were decreased from enterotypes 1 to 5 except for enterotype 2. Collinsella produces ursodeoxycholate. Ursodeoxycholate was previously reported to inhibit binding of SARS-CoV-2 to angiotensin-converting enzyme 2; suppress pro-inflammatory cytokines like TNF-α, IL-1β, IL-2, IL-4, and IL-6; have antioxidant and anti-apoptotic effects; and increase alveolar fluid clearance in acute respiratory distress syndrome. Ursodeoxycholate produced by Collinsella may prevent COVID-19 infection and ameliorate acute respiratory distress syndrome in COVID-19 by suppressing cytokine storm syndrome.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Alveoli
/ Analysis
/ Angiotensin-converting enzyme 2
/ Bacteria
/ Cancer
/ Chronic obstructive pulmonary disease
/ Complications and side effects
/ COVID-19
/ COVID-19 - prevention & control
/ Humans
/ Identification and classification
/ IL-1β
/ Medicine
/ Medicine and Health Sciences
/ Microbiota (Symbiotic organisms)
/ Respiratory distress syndrome
/ rRNA 16S
/ Severe acute respiratory syndrome coronavirus 2
/ Ursodeoxycholic Acid - metabolism
/ Ursodiol
